Neoadjuvant Treatment for Resectable Cancer of the Esophagus and the Gastroesophageal Junction: A Meta-Analysis of Randomized Clinical Trials Authors
Received: 20 March 2002 Accepted: 18 April 2003 DOI:
Cite this article as: Kaklamanos, I.G., Walker, G.R., Ferry, K. et al. Ann Surg Oncol (2003) 10: 754. doi:10.1245/ASO.2003.03.078 Abstract Background: There is no general agreement on the effect of neoadjuvant treatment for esophageal cancer on patient survival. Methods: A meta-analysis was performed to determine the effect of preoperative treatment on survival of patients with resectable esophageal cancer and the effect of preoperative treatment on patient mortality. A standard variance-based method was used to derive summary estimates of the absolute difference in both 2-year survival and treatment-related mortality. Results: Eleven randomized trials involving 2311 patients were analyzed. Preoperative chemotherapy improved 2-year survival compared with surgery alone: the absolute difference was 4.4% (95% confidence interval [CI], .3%–8.5%). Marginal evidence of heterogeneity was eliminated by restricting attention to the four most recent studies, which increased the estimate to 6.3% (95% CI, 1.8%–10.7%). For combined chemoradiotherapy, the increase was 6.4% (nonsignificant; 95% CI, −1.2%–14.0%). Treatment-related mortality increased by 1.7% with neoadjuvant chemotherapy (95% CI, −.9%—4.3%) and by 3.4% with chemoradiotherapy (95% CI, −.1%–7.3%), compared with surgery alone. Conclusions: There seems to be a modest survival advantage for patients who receive neoadjuvant chemotherapy followed by surgery, as compared with surgery alone. There is an apparent increase in treatment-related mortality, mainly for patients who receive neoadjuvant chemoradiotherapy. Key Words: Esophageal cancer Meta-analysis Chemotherapy Radiotherapy Neoadjuvant Survival Download to read the full article text REFERENCES
Jemal A, Thomas A, Murray T, et al. Cancer statistics 1999.
CA Cancer J Clin
2002; 52: 23–47.
Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia.
1991; 265: 1287–9.
Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction.
1993; 104: 510–3.
Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeon Patient Care evaluation study.
J Am Coll Surg
2000; 190: 562–73.
Ellis FH Jr, Heatley GJ, Krasna MJ, et al. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria.
J Thorac Cardiovasc Surg
1997; 113: 836–46.
Mueller JM, Erasmi H, Stelzner M, et al. Surgical therapy of esophageal carcinoma.
Br J Surg
1990; 77: 845–57.
Newaishiy GA, Read GA, Duncan W, et al. Results of radical radiotherapy of squamous cell carcinoma of the esophagus.
1982; 33: 347–52.
Stewart JR, Hoff SJ, Johnson DH, et al. Improved survival with neoadjuvant therapy and resection for adenocarcinoma of the esophagus.
1993; 218: 571–6.
Vogel SB, Mendelhall WM, Sombeek MD, et al. Downstaging esophageal cancer after preoperative radiation and chemotherapy.
1995; 221: 685–95.
Modeling Survival in Medical Research. London: Chapman & Hall, 1994: 25–6.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
1998; 17: 2815–34.
Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis. Methods for Quantitative Synthesis in Medicine. New York: Oxford University Press, 2000: 107–16.
Gignoux M, Roussel A, Paillot B, et al. The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C.
World J Surg
1987; 11: 426–32.
Launois B, Delarue D, Campion JP, et al. Preoperative radiotherapy for carcinoma of the esophagus.
Surg Gynecol Obstet
1981; 153: 690–2.
Wang M, Gu XZ, Yin WB, Huang GJ, Wang LJ, Zhang DW. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients.
Int J Radiat Oncol Biol Phys 1988; 16: 325–7.
Arnott SJ, Duncan W, Kerr GR, et al. Low dose preoperative radiotherapy for carcinoma of the esophagus: results of a randomized clinical trial.
1992; 24: 108–13.
Wright CD, Mathisen DJ, Wain JC, et al. Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction.
Ann Thorac Surg
1994; 58: 1574–8.
Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group).
Int J Radiat Oncol Biol Phys
1998; 41: 579–83.
Orringer MB. Multimodality therapy for esophageal carcinoma-update.
1993; 103 (Suppl 4): 406S–409S.
Murthy SK, Prabhakaran PS, Chandrashekar M, Deshpande R, Doval DC, Gopinath KS. Neoadjuvant Cis-DDP in esophageal cancers: an experience at a regional cancer centre, India.
J Surg Oncol
1994; 45: 173–6.
Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.
N Engl J Med
1985; 312: 1604–8.
Heath EI, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
J Clin Oncol
2000; 18: 868–76.
Seydel HG, Leichman L, Byhardt R, et al. Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG study.
Int J Radiat Oncol Biol Phys
1988; 14: 33–5.
Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.
J Clin Oncol 1993; 6: 1118–23.
Bates BA, Detterbeck FC, Bernard SA, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
J Clin Oncol
1996; 14: 156–63.
Keller SM, Ryan LM, Coia LR, et al. High dose chemo-radiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction. Results of a phase II study of the Eastern Cooperative Oncology Group.
1998; 83: 1908–16.
PubMed CrossRef Copyright information
© The Society of Surgical Oncology, Inc. 2003